Atai Life Sciences NV DEF 14A proxy statements

ATAI Life Sciences and Beckley Psytech announced that the U.S. FDA granted Breakthrough Therapy designation to BPL-003 for treatment-resistant depression, signaling potential for expedited development.

ATAI Life Sciences is moving forward with its acquisition of Beckley Psytech, which reported increased losses but positive Phase 2b results for BPL-003 and secured $10M funding.

ATAI Life Sciences N.V. announced its definitive agreement to acquire Beckley Psytech Limited, following positive Phase 2b clinical trial results for BPL-003 and a $50 million PIPE financing.

ATAI Life Sciences N.V. proposes to acquire Beckley Psytech Limited and redomicile to Delaware, aiming to enhance its psychedelic-based mental health pipeline and streamline corporate structure.

ATAI Life Sciences and Beckley Psytech announced positive Phase 2a clinical trial results for BPL-003, showing improved and sustained antidepressant effects with a two-dose regimen in treatment-resistant depression patients.

ATAI Life Sciences announced positive Phase 2b results for BPL-003 in TRD, a planned strategic combination with Beckley Psytech, and extended cash runway into H2 2027.

ATAI Life Sciences N.V. announced very strong Phase 2b topline data for its BPL-003 (5-MeO-DMT) program, meeting all primary and key secondary endpoints, and secured an additional $50 million in strategic backing from core shareholders including Ferring.

ATAI Life Sciences N.V. announced positive Phase 2b data for BPL-003 (5-MeO-DMT) and a new $50 million investment from core shareholders, including founder Christian Angermayer, extending its financial runway into the second half of 2027.

Atai Life Sciences announced a $50 million private placement financing and positive topline results from Beckley Psytech's Phase 2b clinical study of BPL-003 for treatment-resistant depression, paving the way for a strategic acquisition and extended cash runway.

ATAI Life Sciences announces the strategic acquisition of Beckley Psytech, streamlining its pipeline of short-duration psychedelics and pro-cognitive therapeutics, with several key Phase 2 trial readouts anticipated through early 2026.

ATAI Life Sciences N.V. announces a definitive agreement to acquire Beckley Psytech, aiming to create a leading psychedelic mental health company with a strengthened pipeline, significant IP, and multiple near-term clinical milestones.

atai Life Sciences announced a business combination with Beckley Psytech, aiming to become the leading psychedelic medicine company and will be renamed "atai Beckley" following the closing.

Atai Life Sciences and Beckley Psytech have announced an all-stock business combination, aiming to create a focused pipeline of differentiated psychedelic products for mental health conditions.

Atai Life Sciences announced a definitive agreement to acquire Beckley Psytech in an all-share transaction, creating a combined entity named Atai Beckley N.V., alongside a concurrent $30 million private placement.

atai Life Sciences is set to hold its 2025 Annual General Meeting on May 15, proposing key changes including a shift to a one-tier board and amendments to its articles of association.

Atai Life Sciences N.V. will hold its Annual General Meeting of Shareholders on May 17, 2024, to vote on key proposals including the adoption of annual accounts, appointment of auditors, director appointments, and extension of share issuance authorizations.